Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

NCT03288129 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT03288129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03288129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures
Lead sponsor
Eisai Inc.
Phase
Phase 4
Overall status
Completed
Start date
August 23, 2017
Completion date
April 27, 2021
Enrollment
54 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

partial onset seizures, primary generalized tonic-clonic seizures, secondarily generalized seizures